Alec Gayner

DocwireNews

In a 24-week,&nbsp;randomized trial, a loss-based incentive program&nbsp;motivated&nbsp;patients&nbsp;with&nbsp;ischemic heart disease&nbsp;to&nbsp;engage&nbsp;in more physical activity. The study&nbsp;included 105&nbsp;patients who were&nbsp;divided into a control group and incentive group, stratified by age (&gt;65&nbsp;years&nbsp;vs.&nbsp;&lt;65&nbsp;years).&nbsp;The goal of the study was to increase a participant&rsquo;s daily steps by 15%&nbsp;(ramp-up phase)&nbsp;each week until they reached 10,000 steps per day,&nbsp;at which point&nbsp;they would enter a maintenance period.&nbsp;In the incentive group, patients were given a&nbsp;wrist-worn monitoring device that tracked&nbsp;daily steps. Each participant&nbsp;in the incentive&nbsp;group&nbsp;was allotted $14&nbsp;a week in a virtual account, with $2 deducted for each day the patients failed to meet&nbsp;step goals.&nbsp;Results showed that the incentive group had a much larger change in mean daily steps than the control group. During the ramp-up phase,&nbsp;patients in the incentive group elevated their mean daily steps from their baseline by 1,131, while patients in the control group increased&nbsp;steps&nbsp;by only 276 steps (P&lt;.001). In the maintenance period,&nbsp;the incentive group had an average change from baseline of 1,445 steps,&nbsp;while&nbsp;the control group saw an increase of just 142 (P&lt;.001).&nbsp;In&nbsp;an 8-week follow up, patients in the incentive group maintained a mean increase in steps of 1,225,&nbsp;while patients in the control group fell to a mean increase of just&nbsp;four&nbsp;steps from&nbsp;baseline readings.&nbsp;Source: <a href="http://jaha.ahajournals.org/content/7/12/e009173">JAHA</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Incentive Program Leads to Increased Physical Activity in Patients with Ischemic Heart Disease

Atherosclerotic Disease

In a 24-week, randomized trial, a loss-based incentive program motivated patients with ischemic heart disease to engage in more physical activity. The study included ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe